Skip to content

A Dose-Finding Study of Oxycodone Combined with Propofol for Painless Gastrointestinal Endoscopy in Children

The ED90 of Oxycodone Combined with Propofol for Pediatric Gastrointestinal Endoscopy: A Biased-Coin Sequential Dose-Finding Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128865
Enrollment
Unknown
Registered
2026-07-27
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with gastrointestinal symptoms or suspected digestive system diseases who are scheduled to undergo elective combined gastroscopy and colonoscopy.

Interventions

Oxycodone group:Oxycodone combined with propofol sedation

Sponsors

Capital Center For Children’s Health, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Aged 6–14 years; 2. Scheduled to undergo elective painless gastrointestinal endoscopy; 3. American Society of Anesthesiologists (ASA) physical status I–II; 4. Written informed consent obtained from the subject and their guardian.

Exclusion criteria

Exclusion criteria: 1. Expected need for complex therapeutic endoscopic procedures, such as resection of large polyps, endoscopic hemostasis, dilation, or foreign body removal; 2. Body mass index (BMI) = the 95th percentile, or obvious obesity that may increase the risk of sedation; 3. Significant gastroesophageal reflux, frequent vomiting, intestinal obstruction, or high risk of aspiration; 4. Upper respiratory tract infection, significant cough, fever, or wheezing within the past 2 weeks; 5. Known difficult airway, severe obstructive sleep apnea, or airway malformation; 6. Severe cardiac, pulmonary, hepatic, or renal dysfunction; 7. Neurological disease, developmental delay, or any condition that may affect the assessment of sedation response; 8. Use of opioids, sedative-hypnotics, or other medications that may affect study outcomes within 24 hours before the examination; 9. Allergy to oxycodone, propofol, or other study-related medications; 10. Any other condition that, in the investigator’s judgment, makes the subject unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
ED90 of oxycodone;

Secondary

MeasureTime frame
Use of rescue anesthetic medication;Recovery-period adverse reactions and unplanned medical interventions;Satisfaction of endoscopists, anesthesiologists, and guardians;Overall clinical success rate;procedure duration;Recovery and PACU outcomes;Intra-procedural respiratory and circulatory adverse events;Procedural response events;

Countries

China

Contacts

Public ContactChen Ying

Capital Center For Children’s Health, Capital Medical University

m18754507779@163.com+86 10 8569 5683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026